What is the latest JLHL stock price?
The latest stored price for JLHL is Rs 309.75 as of 2026-08-21.
gimli
JLHL stock AI analysis
JLHL Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
JUPITER LIFE LINE HOSP L is a small-cap stock in Healthcare. This Gimli page shows the latest available JLHL price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹309.75
1W return
-1.90%
1M return
-1.17%
3M return
+18.04%
6M return
+27.82%
1Y return
+11.03%
Market cap
₹2,030.91 cr
PE
53.97
PB
1.32
ROE
+12.97%
ROCE
+14.78%
RSI
46.68
Turnover
₹2.77 cr
Why it can matter in screens
- Momentum: JLHL is above 50DMA, above 200DMA; RSI is 46.68.
- Returns: 1D -2.50%, 1W -1.90%, 1M -1.17%, 3M +18.04%, 1Y +11.03%.
- Trend levels: 52W high ₹340.00, 52W low ₹256.08, off high -8.90%.
- Liquidity: latest turnover is ₹2.77 cr; volume vs 20D is +0.41%.
- Valuation/profitability: PE 53.97, PB 1.32, ROE +12.97%, ROCE +14.78%.
- Growth: 3Y sales CAGR +18.88%, 3Y profit CAGR +38.66%.
Quick Answers
Is JLHL above its 50DMA and 200DMA?
JLHL is above 50DMA, above 200DMA. The latest 50DMA is 301.45 and the latest 200DMA is 275.44.
What are JLHL PE, ROE and ROCE?
JLHL has PE 53.97, ROE +12.97%, and ROCE +14.78% in Gimli's latest available snapshot.
How has JLHL performed recently?
JLHL has returned -1.17% over 1 month, +18.04% over 3 months, and +11.03% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-06-30 | 410.98 cr | 89.86 cr | 37.49 cr | 1.14 |
| 2026-03-31 | 387.84 cr | 99.82 cr | 50.62 cr | 7.66 |
| 2025-12-31 | 365.37 cr | 86.16 cr | 42.55 cr | 5.49 |
| 2025-09-30 | 393.63 cr | 103.52 cr | 57.48 cr | 8.75 |
| 2025-06-30 | 347.62 cr | 90.99 cr | 43.84 cr | 6.69 |
| 2025-03-31 | 336.66 cr | 86.58 cr | 44.00 cr | 6.89 |
| 2024-12-31 | 332.81 cr | 83.55 cr | 52.09 cr | 7.95 |
| 2024-09-30 | 322.58 cr | 84.43 cr | n/a | 7.88 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 1,499.79 cr | 380.74 cr | 194.41 cr | 29.53 |
| 2025-03-31 | 1,302.40 cr | 328.46 cr | 192.03 cr | 29.47 |
| 2024-03-31 | 1,069.50 cr | 260.46 cr | 176.61 cr | 28.44 |
| 2023-03-31 | 892.54 cr | 206.01 cr | 72.91 cr | 11.12 |
| 2022-03-31 | 661.03 cr | 149.93 cr | 84.67 cr | 16.65 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 2,383.13 cr | 54.76 cr | 584.24 cr | 1,544.09 cr |
| 2025-03-31 | 1,904.89 cr | 368.32 cr | 393.14 cr | 1,356.25 cr |
| 2024-03-31 | 1,281.33 cr | 23.01 cr | 0.00 cr | 1,168.74 cr |
| 2023-03-31 | 985.53 cr | 134.46 cr | 468.63 cr | 363.91 cr |
| 2022-03-31 | 908.70 cr | 103.36 cr | 495.25 cr | 288.43 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 267.71 cr | -234.14 cr | n/a |
| 2025-03-31 | 266.74 cr | -60.85 cr | n/a |
| 2024-03-31 | 114.52 cr | 29.23 cr | n/a |
| 2023-03-31 | 117.17 cr | 39.92 cr | n/a |
| 2022-03-31 | 136.97 cr | 45.24 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +40.91% | +9.37% | +16.51% | +10.89% | +33.21% | +0.00% |
| 2026-03-31 | +40.91% | +8.48% | +17.01% | +10.97% | +33.60% | +0.00% |
| 2025-12-31 | +40.91% | +8.48% | +17.43% | +11.55% | +33.17% | +0.00% |
| 2025-09-30 | +40.91% | +9.06% | +16.95% | +10.99% | +33.08% | +0.00% |
| 2025-06-30 | +40.91% | +9.77% | +15.82% | +11.05% | +33.50% | +0.00% |
| 2025-03-31 | +40.91% | +10.03% | +15.63% | +11.09% | +33.42% | +0.00% |
| 2024-12-31 | +40.91% | +10.04% | +15.74% | +11.33% | +33.30% | +0.00% |
| 2024-09-30 | +40.91% | +8.84% | +16.87% | +12.34% | +33.37% | +0.00% |
| 2024-06-30 | +40.91% | +6.06% | +17.27% | +12.81% | +35.76% | +0.00% |
| 2024-03-31 | +40.91% | +4.17% | +17.58% | +13.28% | +37.34% | +0.00% |
| 2023-12-31 | +40.91% | +3.97% | +17.35% | +12.68% | +37.77% | +0.00% |
| 2023-09-30 | +40.91% | +4.62% | +16.14% | +11.57% | +38.32% | +0.00% |
| 2023-09-13 | +40.91% | +3.38% | +10.12% | +4.22% | +45.58% | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 456,449.49 cr | 37.677543 | +15.50% | +15.99% |
| DIVISLAB | DIVI S LABORATORIES LTD | 228,223.36 cr | 78.319614 | +18.37% | +42.62% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 165,719.79 cr | 75.983398 | +17.33% | +34.25% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 124,992.04 cr | 63.823550 | +21.03% | +9.67% |
| CIPLA | CIPLA LTD | 115,693.19 cr | 34.304976 | +10.25% | -10.08% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 112,698.21 cr | 22.474914 | +17.93% | +13.61% |
| LUPIN | LUPIN LIMITED | 100,669.80 cr | 14.727517 | +34.34% | +12.19% |
| MANKIND | MANKIND PHARMA LIMITED | 98,418.27 cr | 47.977550 | +13.18% | -8.31% |
Try these prompts
- Analyze JUPITER LIFE LINE HOSP L with valuation, momentum and industry peers
- Compare JLHL with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare JLHL with other Healthcare stocks
Data snapshot: 2026-08-21. Not investment advice.